Evidence map›Paper›PMID 29732713›Full record

Observational studyArthritis & rheumatology (Hoboken, N.J.)2018

Risk Factors and Biomarkers for the Occurrence of Uveitis in Juvenile Idiopathic Arthritis: Data From the Inception Cohort of Newly Diagnosed Patients With Juvenile Idiopathic Arthritis Study.

Christoph Tappeiner, Jens Klotsche, Claudia Sengler, Martina Niewerth, Ina Liedmann, Karoline Walscheid, Miha Lavric, Dirk Foell, Kirsten Minden, Arnd Heiligenhaus

Open access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Arthritis & rheumatology (Hoboken, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. A clearer vision: insights into juvenile idiopathic arthritis-associated uveitis.Proceedings (Baylor University. Medical Center) · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Uveitis in Children and Adolescents.Rheumatic diseases clinics of North America · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Christoph TappeinerInselspital, University of Bern, Bern, Switzerland, German Rheumatism Research Center, Berlin, Germany, and St. Franziskus Hospital, Muenster, Germany.ORCID 0000-0001-6907-1112
Jens KlotscheGerman Rheumatism Research Center and Charité Universitätsmedizin Berlin, Berlin, Germany.
Claudia SenglerGerman Rheumatism Research Center, Berlin, Germany.
Martina NiewerthGerman Rheumatism Research Center, Berlin, Germany.
Ina LiedmannGerman Rheumatism Research Center, Berlin, Germany.
Karoline WalscheidSt. Franziskus Hospital, Muenster, Germany.
Miha LavricUniversity of Muenster, Muenster, Germany.
Dirk FoellUniversity of Muenster, Muenster, Germany.
Kirsten MindenGerman Rheumatism Research Center and Charité Universitätsmedizin Berlin, Berlin, Germany.
Arnd HeiligenhausSt. Franziskus Hospital, Muenster, Germany.
German Rheumatism Research Centre · DESt. Franziskus Hospital · DEUniversity of Münster · DEUniversity of Bern · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo analyze the prognostic value of demographic, clinical, and therapeutic factors and laboratory biomarkers and to assess their role in predicting uveitis occurrence in patients with juvenile idiopathic arthritis (JIA).

methodsPatients with JIA were enrolled within the first year after JIA diagnosis. Demographic and clinical parameters were documented. Serum samples were collected at study enrollment, at 3-month follow-up visits within the first year, and then every 6 months. A multivariable Cox regression analysis was performed to evaluate the impact of demographic, clinical, laboratory, and therapeutic parameters on uveitis onset.

resultsWe included 954 JIA patients (67.2% female, 54.2% antinuclear antibody [ANA] positive, mean ± SD age at onset 7.1 ± 4.6 years). Uveitis occurred in 133 patients (observation period 44.5 months). Young age at JIA onset and ANA positivity were significantly associated with the onset of uveitis (both P < 0.001). Treatment of arthritis with methotrexate alone (hazard ratio [HR] 0.18 [95% confidence interval (95% CI) 0.12-0.29], P < 0.001) or combined with etanercept (HR 0.10 [95% CI 0.04-0.23], P < 0.001) or adalimumab (HR 0.09 [95% CI 0.01-0.61], P = 0.014) reduced the risk of uveitis onset and the occurrence of uveitis-related complications. Predictors of uveitis onset included elevated erythrocyte sedimentation rate at baseline (HR 2.36 [95% CI 1.38-4.02], P = 0.002) and continuing moderate or high disease activity during follow-up as measured by the 10-joint clinical Juvenile Arthritis Disease Activity Score (HR 4.30 [95% CI 2.51-7.37], P < 0.001). Additionally, S100A12 levels ≥250 ng/ml at baseline were significantly associated with the risk of uveitis (HR 2.10 [95% CI 1.15-3.85], P = 0.016).

conclusionApart from demographic risk factors and treatment modalities, JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Indexed as

Severity of Illness IndexAdalimumabAntirheumatic AgentsArthritis, JuvenileBiomarkersBlood SedimentationChildChild, PreschoolEtanerceptFemaleFollow-Up StudiesHumansMaleMethotrexateMultivariate AnalysisPredictive Value of TestsAdalimumabAntirheumatic AgentsBiomarkersEtanerceptMethotrexate

Identifiers

PMID29732713
PMCPMC6174956
OpenAlexW2802575379

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.